Splenectomy and Complement Regulation in Erythrocytes: Implications for Hemolysis in Pediatric β-Thalassemia Major
Keywords:
β-thalassemia major; Hemolysis; CD55; CD59; Pediatric hematology; Ineffective Erythropoiesis; Thromboembolic ComplicationsAbstract
β-Thalassemia major is a hereditary hemoglobinopathy characterized by ineffective erythropoiesis, chronic anemia, and enhanced red blood cell (RBC) destruction. Hemolysis in this disorder results from both intrinsic membrane defects and extrinsic immune-mediated mechanisms. The spleen plays a central role in culling defective erythrocytes and regulating immune responses, including complement activation. Splenectomy is frequently performed in pediatric β-thalassemia major to ameliorate transfusion requirements and reduce extravascular hemolysis. However, removal of the spleen alters key pathways of complement regulation on erythrocyte surfaces, potentially exacerbating hemolytic processes. This review synthesizes current evidence on the interplay between splenic function, complement regulatory proteins (e.g., CD55, CD59), and erythrocyte survival in β-thalassemia major. We examine how splenectomy modifies complement system dynamics, leading to changes in opsonization, membrane attack complex formation, and susceptibility to intravascular hemolysis. Additionally, we discuss emerging biomarkers for complement activation, the impact of chronic transfusion therapy, and the risk of thromboembolic complications post-splenectomy. Understanding these mechanisms deepens insight into the pathophysiology of hemolysis in pediatric β-thalassemia major and highlights potential therapeutic targets to mitigate complement-mediated RBC destruction while optimizing patient outcomes.
Downloads
References
1. Merchant, R. H., Shah, A. R., Ahmad, J., Karnik, A., & Rai, N. (2015). Post splenectomy outcome in β-thalassemia. The Indian Journal of Pediatrics, 82(12), 1097-1100.
2. Kurtoğllu, A. U., Koçtekin, B., Kurtoğlu, E., & Yildiz, M. (2019). The effect of splenectomy on complement regulatory proteins in erythrocytes in β-thalassemia major. Archives of Medical Science, 15(1), 191-195.
3. Atichartakarn, V., Chuncharunee, S., Archararit, N., Udomsubpayakul, U., & Aryurachai, K. (2014). Intravascular hemolysis, vascular endothelial cell activation and thrombophilia in splenectomized patients with hemoglobin E/β-thalassemia disease. Acta Haematologica, 132(1), 100-107.
4. Ali, S., Mumtaz, S., Shakir, H. A., Khan, M., Tahir, H. M., Mumtaz, S., ... & Khan, M. A. (2021). Current status of beta‐thalassemia and its treatment strategies. Molecular genetics & genomic medicine, 9(12), e1788.
5. Ammar, S. A., Elsayh, K. I., Zahran, A. M., & Embaby, M. (2014). Splenectomy for patients with β-thalassemia major: long-term outcomes. The Egyptian Journal of Surgery, 33(4).
6. Gluba-Brzózka, A., Franczyk, B., Rysz-Górzyńska, M., Rokicki, R., Koziarska-Rościszewska, M., & Rysz, J. (2021). Pathomechanisms of immunological disturbances in β-thalassemia. International Journal of Molecular Sciences, 22(18), 9677.
7. Obaid, J. M., Abo El-Nazar, S. Y., Ghanem, A. M., El-Hadidi, A. S., & Mersal, B. H. (2015). Compensation of CD55 underexpression on red blood cells of β-thalassemia major patients. Hemoglobin, 39(3), 184-189.
8. Evangelidis, P., Evangelidis, N., Vlachaki, E., & Gavriilaki, E. (2024). What is the role of complement in bystander hemolysis? Old concept, new insights. Expert Review of Hematology, 17(4-5), 107-116.
9. Zahira, A. F., Wasono, A. R. P., Yudho, S. U., & Bintoro, H. K. (2022). The Role of Splenectomy in The Treatment of β-Thalassemia Major Patients: A Literature Review. The Role of Splenectomy in The Treatment of β-Thalassemia Major Patients: A literature review, 115(1), 6-6.
10. Roumenina, L. T., Bartolucci, P., & Pirenne, F. (2019). The role of complement in post-transfusion hemolysis and hyperhemolysis reaction. Transfusion medicine reviews, 33(4), 225-230.
11. Maciel, T. T., Sbeih, N., Rignault-Bricard, R., Chevalme, I., Allali, S., Brochier, C., ... & Hermine, O. (2024). Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia. Blood, 144, 3870.
12. Cho, H. (2015). Complement regulation: physiology and disease relevance. Korean journal of pediatrics, 58(7), 239.
13. Thielen, A. J., Zeerleder, S., & Wouters, D. (2018). Consequences of dysregulated complement regulators on red blood cells. Blood Reviews, 32(4), 280-288.
14. Alegretti, A. P., Schneider, L., Piccoli, A. K., & Xavier, R. M. (2012). The role of complement regulatory proteins in peripheral blood cells of patients with systemic lupus erythematosus. Cellular immunology, 277(1-2), 1-7..
15. Darzi, A. A., Kamali, S., & Khakzad, M. (2015). Influence of splenectomy on immunoglobulins and complement components in major thalassemia. Caspian journal of internal medicine, 6(1), 30.
16. Awad, A. S., Ali, H. A., & Althalmi, S. A. A. (2023). Assessment of serum fractalkine level as potential role for complications in splenectomized and non-splenectomized patients with β-thalassemia major. Anaesthesia, Pain & Intensive Care, 27(5), 495-500.
17. Miri-Aliabad, G., Rezaeifar, A., & Salarzaei, M. (2022). Comparison of immunoglobulins status in splenectomized and non-splenectomized patients with major beta-thalassemia. Journal of Pediatrics Review, 10(2), 161-166.
18. Mizher, E. A. (2024). Immunological Changes and Complement Proteins in Major Thalassemia Patients Proteins Post-Splenectomy: Perubahan Imunologi dan Protein Komplemen pada Pasien Talasemia Mayor Protein Pasca-Splenektomi. Academia Open, 9(2).
19. Mahmoud, S. S., Mohamed, G. B., Hakeem, G. L. A., Higazi, A. M., Nafady, A. A. H., Farag, N. M., ... & Shaban, A. (2017). Comparison of the immunity status in-between children with [beta]-thalassaemia major receiving different treatment modalities: a single Egyptian district study. Immunome Research, 13(1), 1.
20. Beshir, M. R., Abd-Alaziz, M. B., Ismail, W. I., & Baz, E. G. (2024). Evaluation of Immune System Alterations in Children with β-Thalassemia Major: Single-Center Egyptian Study. Zagazig University Medical Journal, 30(6), 2280-2289.
21. Zahran, A. M., Shaltout, A. S., Hamada, I. H., Mohammed, A. M., Abo Elgheet, A. M., & Elsayh, K. I. (2020). Assessment of complement regulatory proteins CD55 and CD59 on erythrocytes in beta-thalassemia major patients. Egypt J Immunol, 27, 109-118.
22. McCarthy, P., & Smith, O. P. (2023). Hematological problems in pediatric surgery. In Pediatric Surgery: Diagnosis and Management (pp. 119-144). Cham: Springer International Publishing.
23. Sari, T. T., Gatot, D., Akib, A. A., Bardosono, S., Hadinegoro, S. R., Harahap, A. R., & Idjradinata, P. S. (2014). Immune response of thalassemia major patients in Indonesia with and without splenectomy. Acta Medica Indonesiana, 46(3).
24. Abo-Elwafa, H. A., Youseff, L. M., Mahmoud, R. A., Elbadry, M. I., Tawfeek, A., & Aziz, S. P. (2023). Venous thromboembolism risk assessment among Beta-thalassemia patients. Journal of Applied Hematology, 14(3), 230-235.
25. Lal, A., Wong, T. E., Andrews, J., Balasa, V. V., Chung, J. H., Forester, C. M., ... & Vichinsky, E. P. (2018). Transfusion practices and complications in thalassemia. Transfusion, 58(12), 2826-2835.
26. Bazi, A., Shahramian, I., Yaghoobi, H., Naderi, M., & Azizi, H. (2018). The role of immune system in thalassemia major: a narrative review. Journal of Pediatrics Review, 6(2), 29-36.
27. Zanetti, R. C., Vasta, L. M., Romanelli, K., & Newton, T. C. (2021). Management of hyperhemolysis in β-thalassemia with multiple immunosuppressives, including complement blockade. Journal of pediatric hematology/oncology, 43(8), e1145-e1147.
28. Caocci, G., Mulas, O., Barella, S., Orecchia, V., Mola, B., Costa, A., ... & La Nasa, G. (2023). Long-term health-related quality of life and clinical outcomes in patients with β-thalassemia after splenectomy. Journal of clinical medicine, 12(7), 2547.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
